Reviva Pharmaceuticals Holdings, Inc.
brilaroxazine
schizophrenia
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews brilaroxazine for schizophrenia around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“The Company is optimistic about receiving FDA alignment on this strategy, with feedback expected mid-year 2026.”